INTRODUCTION
Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat infections caused from these organisms has fallen short of the emergent need. Specifically, resistance among Staphylococcus aureus and Enterococcus spp. to essential antibiotics in the US is considered a major problem with 56.8% of S. aureus being methicillin-resistant (MRSA) and 87.1% of Enterococcus faecium being vancomycin resistant (VRE) [1] . Additionally, data from the most recent US National Healthcare Safety
Network and Center for Disease Control and
Prevention's report identified these two organisms as being the most commonly reported organisms isolated from hospital-acquired infections [2] . With the high frequency of these organisms implicated in serious infections and the concerns with their resistance to the mainstay of treatment, there is clearly a need for alternative therapies. Oritavancin is a semisynthetic lipoglycopeptide antibiotic that is one of the new agents that was recently approved for the treatment of acute Gram-positive skin and skin structure infections. This review will focus on oritavancin's spectrum of activity, mechanisms of action and resistance, pharmacokinetic and pharmacodynamic properties, and the completed and ongoing clinical studies evaluating its use. The search for articles in this review was performed using the search terms oritavancin and LY33328 with the PubMed database for articles published between the dates of 2010 to 2015.
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CHEMICAL STRUCTURE
Oritavancin is a lipoglycopeptide derived from the naturally occurring chloroeremomycin, a member of the eremomycin class of glycopeptides [3] . While structurally similar to vancomycin ( Fig. 1) , the eremomycin-glycopeptides possess two 4-epi-vancosamine monosaccharides, one replacing vancosamine and the other linked to ring-6 via an amino acid residue. Oritavancin additionally includes a highly hydrophobic N-alkyl-p-chlorophenylbenzyl substituent linked to the disaccharide sugar. These pharmacophore features, as well as associated modifications in stereochemistry, are believed to be largely responsible for the greatly enhanced antimicrobial potency of oritavancin against Gram-positive organisms including those possessing both VanAand VanB-mediated vancomycin-resistance [4] . Oritavancin, while structurally related to vancomycin, possesses unique mechanisms of action secondary to the inclusion of the highly hydrophobic N-alkyl-p-chlorophenylbenzyl [10, 12] . This membrane-targeted mechanism of action is proposed to be independent of [36] . In a rabbit model of meningitis caused by Streptococcus pneumoniae, a single dose of oritavancin was shown to reduce bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as continuous infusion ceftriaxone [37] . Maximum concentrations of oritavancin in the CSF were reached several hours after administration, and although the estimated CSF penetration was relatively low at 1-5%, the highly active in vivo activity resulted in reduced bacterial titers, decreased inflammatory markers, and sterilization of the CSF. However, the tolerability of such high doses needed to penetrate into the CSF is still to be determined in humans. Oritavancin has also been studied in rabbits to determine the differential distribution from serum to bone tissue [40] . 
MECHANISMS OF ACTION AND RESISTANCE

